ATHE

MKT CAP:$39M

Alterity Therapeutics Limited

Market Cap

$39M

Healthcare·Biotechnology·🇦🇺 Australia·NASDAQ

Healthcare·Biotechnology·🇦🇺·NASDAQ

Stock Price

$4.37+$1.21 (+38.29%)

Apr 23, 2026

Company Details

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candida...

CEO

David A. Stamler

IPO Date

Sep 29, 2003

Website

alteritytherapeutics.com

Key Metrics TTM

Revenue

$4M

+18.6% YoY

Net Income

-$27M

EPS (Diluted)

-$3.26

Free Cash Flow

-$15M

Revenue / Share

$0.26

Gross Margin

96.0%

Operating Margin

-720.7%

Net Margin

-609.8%

FCF Margin

-354.1%

P/S

8.9x

P/E

—

Earnings Reports

Q2 2026

Jan 30, 2026

$0-100.0%EPS -$0.39

FY 2025

Aug 28, 2025

$4M+35.3%EPS -$0.81

Q2 2025

Feb 28, 2025

$1MEPS -$0.60

FY 2024

Sep 26, 2024

$3M+2.6%EPS -$2.23

Q4 2024

Sep 26, 2024

$2MEPS -$0.86

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 16	$1M	$1M	-$3M
Q2 17	$1M	$1M	-$3M
Q4 17	$893.7K	$798.4K	-$2M
Q2 18	$1M	$980.1K	-$2M
Q4 18	$1M	$1M	-$4M
Q2 19	$2M	$2M	-$4M
Q4 19	$2M	$2M	-$5M
Q2 20	$1M	$1M	-$4M
Q4 20	-$1M	-$2M	-$6M
Q2 21	$1M	$1M	-$7M
Q2 22	$2M	$2M	-$7M
Q4 22	$2M	$2M	-$7M
Q2 23	$2M	$2M	-$8M
Q4 24	$2M	$1M	-$9M
Q2 25	$1M	$1M	-$5M
Q2 26	$0	-$40.6K	-$9M

Valuation

Quarter	P/S	P/E
Q4 16	4.8x	—
Q2 17	5.5x	—
Q4 17	6.8x	—
Q2 18	8.2x	—
Q4 18	8.7x	—
Q2 19	8.0x	—
Q4 19	6.8x	—
Q2 20	6.5x	—
Q4 20	11.0x	—
Q2 21	12.4x	—
Q2 22	12.9x	—
Q4 22	10.6x	—
Q2 23	5.8x	—
Q4 24	5.7x	—
Q2 25	6.2x	—
Q2 26	8.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 16	-$28.6K	-$29.0K
Q2 17	-$443.4K	-$459.3K
Q4 17	-$4M	-$4M
Q2 18	-$837.4K	-$839.8K
Q4 18	-$4M	-$4M
Q2 19	-$5M	-$5M
Q4 19	-$5M	-$5M
Q2 20	-$2M	-$2M
Q4 20	-$5M	-$5M
Q2 21	-$5M	-$5M
Q2 22	-$6M	-$6M
Q4 22	-$182.8K	-$246.4K
Q2 23	-$4M	-$4M
Q4 24	-$6M	-$6M
Q2 25	-$6M	-$6M
Q2 26	-$7M	$0

Capital Expenditures

Quarter	CapEx
Q4 16	$408
Q2 17	$15.8K
Q4 17	$4.1K
Q2 18	$2.4K
Q4 18	$42.2K
Q2 19	$2.3K
Q4 19	$2.9K
Q2 20	$5.4K
Q4 20	$6.6K
Q2 21	$1.8K
Q2 22	$1.8K
Q4 22	$63.6K
Q2 23	$3.5K
Q4 24	$199
Q2 25	$0
Q2 26	$7M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 16	-68.9%	-42.6%
Q2 17	-44.4%	-23.8%
Q4 17	-59.2%	-56.5%
Q2 18	-48.3%	-36.2%
Q4 18	-19.2%	+6.0%
Q2 19	+27.5%	+32.7%
Q4 19	+101.7%	+141.1%
Q2 20	+25.6%	+69.4%
Q4 20	-212.5%	-8.0%
Q2 21	-22.4%	+43.5%
Q2 22	-6.6%	+30.3%
Q4 22	+49.0%	+74.1%
Q2 23	+228.6%	+108.9%
Q4 24	+12.5%	+31.0%
Q2 25	-31.9%	-27.4%
Q2 26	-100.0%	-3.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 16	$0	0.0%
Q2 17	$0	0.0%
Q4 17	$17.5K	2.0%
Q2 18	$116.0K	11.0%
Q4 18	$430.0K	36.5%
Q2 19	$56.5K	3.3%
Q4 19	$7.2K	0.4%
Q2 20	$0	0.0%
Q4 20	-$8.6K	—
Q2 21	$1M	83.8%
Q2 22	$625.1K	37.1%
Q4 22	$450.5K	22.8%
Q2 23	$447.9K	26.3%
Q4 24	$406.8K	26.9%
Q2 25	$800.7K	69.8%
Q2 26	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 16	$3M	$1M	$34.8K	—
Q2 17	$3M	$1M	$35.4K	—
Q4 17	$1M	$1M	$36.3K	—
Q2 18	$2M	$1M	$31.6K	—
Q4 18	$3M	$2M	$19.1K	—
Q2 19	$4M	$1M	$26.3K	—
Q4 19	$5M	$2M	$42.2K	—
Q2 20	$4M	$1M	$21.7K	—
Q4 20	$3M	$1M	$21.7K	—
Q2 21	$4M	$3M	$23.8K	—
Q2 22	$5M	$2M	$10.9K	—
Q4 22	$6M	$2M	$17.5K	—
Q2 23	$6M	$2M	$13.3K	—
Q4 24	$9M	$2M	—	—
Q2 25	$4M	$2M	$240.1K	—
Q2 26	$5M	—	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 18	$11M	$6.8K	$11M
Q2 19	$6M	$0	$6M
Q4 19	$10M	$0	$10M
Q2 20	$9M	$0	$9M
Q4 20	$7M	$0	$7M
Q2 21	$25M	$0	$25M
Q4 21	$20M	$0	$20M
Q2 22	$26M	$0	$26M
Q4 22	$25M	$0	$25M
Q2 23	$18M	$0	$18M
Q4 23	$11M	$0	$11M
Q2 24	$9M	$0	$9M
Q4 24	$9M	$0	$9M
Q2 25	$3M	$0	$3M
Q4 25	$24M	$5M	$29M
Q2 26	$35M	$0	$35M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 16	890K	0.0%	+17.8%
Q2 17	890K	0.0%	+9.2%
Q4 17	893K	+0.4%	+3.8%
Q2 18	890K	-0.4%	0.0%
Q4 18	890K	0.0%	0.0%
Q2 19	895K	+0.5%	+0.5%
Q4 19	1M	+29.2%	+29.4%
Q2 20	1M	+25.2%	+62.6%
Q4 20	2M	+6.1%	+72.6%
Q2 21	2M	+43.6%	+146.5%
Q2 22	4M	+81.7%	+246.7%
Q4 22	4M	+0.1%	+177.2%
Q2 23	4M	+0.2%	+161.8%
Q4 24	11M	+161.5%	+376.7%
Q2 25	9M	-15.8%	+120.9%
Q2 26	17M	+91.6%	+322.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 16	$121.4K	12
Q2 17	$113.3K	12
Q4 17	$68.7K	13
Q2 18	$81.2K	13
Q4 18	$84.1K	14
Q2 19	$123.8K	14
Q4 19	$128.8K	14
Q2 20	$94.6K	14
Q4 20	-$110.4K	12
Q2 21	$112.1K	12
Q2 22	$153.2K	11
Q4 22	$164.5K	12
Q2 23	$142.0K	12
Q4 24	$151.3K	10
Q2 25	$114.7K	10
Q2 26	$0	9

Revenue / Employee